Parasite | Eso | Sto | Cancer | ESD
[À§¾Ï 251 - Mantle cell lymphoma]
001 | 101 | 201 | 301 | 401 | 501 | 601 | 701 | 801 | 901 | 1000
1. Mantle zoneÀº ¾îµðÀΰ¡? Mantle cell lymphomaÀÇ Á·º¸´Â?
2. Mantle cell lymphomaÀÇ ÀÓ»óÀû Ư¡
°¡Àå Áß¿äÇÑ Æ¯Â¡Àº óÀ½ ¹ß°ß½Ã systemic diseaseÀÎ °æ¿ì°¡ ´ëºÎºÐÀ̶ó´Â °ÍÀÔ´Ï´Ù. À§Àå°üµµ ´ëºÎºÐÀÇ °æ¿ì¿¡ ÀÌ¹Ì Ä§À±µÇ¾î ÀÖ´Ù°í ÇÕ´Ï´Ù (World J Gastroenterol. 2010).
1) Subtype of B cell NHL
2) Typically present with widespread adenopathy and frequently have bone marrow and extranodal involvement (Lymph nodes > 90%, Bone marrow 70-80%, Spleen 60%, Liver 30%, GI tract 20-30%), Peripheral blood (lymphocytosis) 20-30%)
3) GI tract involvement: °ú°Å¿¡´Â 10-20% Á¤µµ·Î »ý°¢ÇÏ¿´À¸³ª ÃÖ±Ù¿¡´Â 80-90%·Î º¸°í ÀÖÀ½
4) Most common type in GI tract: lymphomatous polyposis
5) Pathologically low-grade, clinically high-grade
6) 3-10% of all lymphoma cases
7) Mean age at presentation: 60 years
8) M:F = 3:1
9) Stage III-IV at presentation (70-80% of cases)
10) Poor prognosis: 5 years OS ¡Â 30%
11) Best treatment modality: uncertain
3. Mantle cell lymphoma of the GI tract
1) Most common site: ileo-cecal region
2) Any other area may be involved: from the stomach to the rectum
3) Most patients have extensive nodal and bone marrow disease at presentation
4) Symptoms: abdominal pain, diarrhea, hematochezia --> non-specific
´ÙÀå±â ħ¹üÀº ÀϹÝÀûÀÎ Çö»óÀÔ´Ï´Ù. ½ÉÁö¾î À°¾È¼Ò°ßÀÌ Á¤»óÀÎ °æ¿ì¶óµµ Á¶Á÷°Ë»ç¸¦ ÇÏ¸é ½ÊÀÌÁöÀåÀ̳ª ´ëÀå ħ¹üÀÌ ÈçÈ÷ ¹ß°ßµË´Ï´Ù.